Form 8-K - Current report:
SEC Accession No. 0000950170-24-035365
Filing Date
2024-03-22
Accepted
2024-03-22 16:15:16
Documents
14
Period of Report
2024-03-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lctx-20240312.htm   iXBRL 8-K 54742
2 EX-1.1 lctx-ex1_1.htm EX-1.1 320292
3 EX-5.1 lctx-ex5_1.htm EX-5.1 16028
4 GRAPHIC img133474293_0.jpg GRAPHIC 6997
  Complete submission text file 0000950170-24-035365.txt   580087

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lctx-20240312.xsd EX-101.SCH 23882
17 EXTRACTED XBRL INSTANCE DOCUMENT lctx-20240312_htm.xml XML 4516
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 24775407
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)